PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “POTASSIUM CHLORIDE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1978

Comparison of the taste and acceptance of three potassium chloride preparations.

The palatability and acceptance of three commercially available potassium chloride solutions were evaluated. Adult ambulatory patients routinely self-administering potassium chloride solution rate the palatability and acceptance of each preparation. An open-label, three-treatment crossover study design was used. The taste of Klorvess was rated significantly more palatable than Kaochlor (p less than 0.01) or KayCiel (p less than 0.05). Klorvess was rated significantly more acceptable if taken over a long period of time than Kaochlor (p less than 0.01) or KayCiel (p less than 0.01). The average amount consumed of all three products was 57% of the prescribed amount. The amount of Klorvess returned was significantly less than the amount of either KayCiel (p less than 0.01) or Kaochlor (p less than 0.01). The flavoring agents are described and the importance of ensuring that the patient uses an accurate measuring spoon is discussed.

Administration, Oral↗
PubMed1985

Ulceration of the small intestine due to slow-release potassium chloride tablets.

A retrospective study at surgical clinics in Stockholm County disclosed 22 cases of small-bowel ulceration in which a connection with use of slow-release potassium chloride tablets was probable. Most ulcers had caused stenosis of 1-2 cm of gut, and in four of these cases there was also perforation of the bowel wall. Five patients had perforation without signs of stenosis. The pathology of the ulcers was similar to that described after use of enteric-coated potassium chloride tablets. Since 1970 the frequency of potassium-induced ulceration has been low--3 cases per 100 000 patient-years of slow-release tablet use. On the other hand, this complication of drug therapy can be serious--the mortality in the present series was 27%. Other types of potassium chloride preparations should therefore be tested. Microencapsulated potassium chloride tablets have been reported to be less irritating to the gastrointestinal tract.

Aged↗
PubMed1980

Bartter's syndrome with normal urinary excretion of prostaglandin E: therapeutic effects of propranolol, spironolactone, indomethacin and potassium chloride.

Urinary excretion of prostaglandin E (PGE) in 8 patients with Bartter's syndrome measured by the radioimmunoassay method was not augmented over the normal values. In one of them, urinary excretion of sodium, potassium, chloride and PGE, serum sodium, potassium and chloride, plasma renin activity and plasma aldosterone concentration were studied before and after the administration of propranolol, spironolactone, indomethacin and potassium chloride. Neither propranolol nor spironolactone affected any of these parameters. Indomethacin promptly reduced urinary excretion of sodium, potassium, chloride and PGE, and markedly suppressed the renin-aldosterone system. Serum potassium was elevated, but remained still in hypokalemic range. Potassium chloride was most effective in raising the serum potassium level during the first 4 weeks of administration. These results suggest that overproduction of renal PGs is not the primary cause of Bartter's syndrome, and that the renal potassium wastage is one of the etiological factors in this syndrome. It has also been suggested that hyperreninemia in this syndrome was associated in some way with renal PGs, not PGE but other series of PGs.

Adult↗
PubMedDate not supplied

Homogeneity of potassium chloride in small volume intravenous containers.

The purpose of this investigation was to determine whether potassium chloride as an additive is distributed homogeneously throughout small volume parenteral solutions and whether the pattern of electrolyte distribution is identical for two types of delivery systems. The effect of purposeful mixing after addition of potassium chloride was also studied. Thirty-one registered nurses prepared two supplementary intravenous solutions consisting of 10mEq potassium chloride in 50ml of 5% dextrose solution. One solution was prepared in a soft polyvinyl chloride minibag (Viaflex, Baxter-Travenol), the other in a semirigid plastic burette (Buretrol, Baxter-Travenol). The solutions were discharged through a volumetric pump (IMED) and four aliquots were taken at regular intervals. Samples were chemically analyzed by flame photometry to determine the potassium concentration in each solution layer of the container. For each container type, there were significant differences in the potassium concentrations among the layers of solution. The pattern of distribution also differed significantly between the two containers. The strata in the minibag showed smaller variations in potassium concentration than did corresponding layers in the burette. Some single sample concentrations from burettes exceeded the expected concentration of 200mEq/L by 105mEq. Nurses manipulated the two types of containers differently. Thirty of 31 minibags were mechanically mixed, but only 11 of 31 burettes were treated in this way. When the effect of mixing was considered, solutions in mixed containers were essentially no different from those not agitated after addition of the electrolyte.

Drug Packaging↗
PubMed1975

Potassium chloride preparations and fecal blood loss. A parallel study with a 10 percent solution and a non-enteric-coated waxy-matrix tablet.

Concentrated potassium chloride produces ulceration of the gastrointestinal mucosa. Dilute solutions are frequently not acceptable to the patient. A tablet containing potassium chloride crystals suspended in a waxy matrix has been developed to avoid these drawbacks. We measured fecal blood loss by a radioactive chromium technique on 20 subjects during five days while they were given potassium chloride, 40mEq/day; ten subjects took a 10% solution; the others the waxy-matrix tablet. Fecal blood loss did not differ significantly between these groups. Mean fecal blood losses in both groups were slightly increased during the potassium chloride administration but never exceeded acceptable normal limits.

Adult↗
PubMed2003

Design and evaluation of sustained release microspheres of potassium chloride prepared by Eudragit.

The aim of the present work was to prepare and evaluate the sustained release of potassium chloride formulations. Eudragit RS and/or RL loaded with potassium chloride microspheres were prepared by a solvent evaporation method. The effect of sustained release of Eudragit microspheres was evaluated by an in vitro dissolution test and in vivo oral absorption study, and the results were compared to a commercial product (Slow-K). The results showed that Eudragit microspheres loaded with potassium chloride can be easily prepared and satisfactory results obtained considering the size distribution and shapes of microspheres by incorporating aluminum stearate. The encapsulation efficiency and loading capacity were about 84-90% and 27%, respectively. Moreover, the Eudragit RS (30-45 mesh) and Eudragit RS/RL (20-30 mesh) microspheres showed a similar sustained release effect of commercial product via in vitro dissolution and in vivo oral absorption study.

Animals↗
PubMed1999

Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.

OBJECTIVE: To study the compatibility of tirofiban HCl injection 0-05 mg/ml with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride infusion solutions during simulated Y-site administration. METHOD: Tirofiban HCl, dopamine HCl, famotidine, lidocaine HCl and potassium chloride infusions were each prepared from their respective concentrates as per current clinical preparation instructions in both 0.9% sodium chloride and 5% dextrose solutions at both the minimum and maximum concentrations normally administered. Sodium heparin premixed infusion solutions in 5% dextrose and 0-45% sodium chloride were used as-is. Tirofiban HCl solutions were combined 1:1 (simulated Y-site administration) with the dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride solutions in separate glass containers and polyvinylchloride Y-site infusion lines. Samples were held for 4 h at room temperature under ambient fluorescent light and were assayed for changes in drug content, degradation, pH, appearance and turbidity. Activity of sodium heparin solutions was measured using an aPTT coagulation assay. RESULTS: All mixtures remained clear and colourless with no visual indication of instability, i.e. precipitation. Clarity of solutions was confirmed by turbidometric analysis. There was no significant loss of drug, increase in known degradates, or appearance of unknown drug-related peaks as determined by HPLC. The activity of heparin in heparin-containing solutions remained unchanged. The pH of all test-solutions remained constant. CONCLUSION: Tirofiban HCl injection 0.05 mg/ml can be co-infused by Y-site administration with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride injection solutions.

Chromatography, High Pressure Liquid↗
PubMed1980

Plasma aldosterone response to angiotensin II and potassium chloride infusions in hypopituitary patients.

The acute adrenal response to potassium chloride and angiotensin II (A II) infusions was studied in hypopituitary patients and compared with normal subjects. The peripheral plasma levels of aldosterone (PAC), cortisol (F), potassium (K), and plasma renin activity (PRA), were measured at 09.00 h and after 60 and 120 min of infusion. All subjects were recumbent ad under balance conditions, receiving a daily dietary intake of 180 mmol of sodium and 80 mmol of potassium. Basal PAC in hypopituitary patients was not significantly different from that observed in the control group. Both normal and hypopituitary patients respond to A II infusion with significant increments. Under potassium chloride stimulus the PAC response in hypopituitary patients was only observed when cortisol (20 mg) was given 2 h prior to the infusion. When cortisol replacement was omitted the response KCl was not detected. These results suggest a permissive role of cortisol on glomerulosa response to potassium.

Adrenal Glands↗
PubMed1981

Preparation and release characteristics of potassium chloride microcapsules.

The release characteristics of potassium chloride was studied when it was coated with a selection of polymers; from the results obtained, a suitable batch was microencapsulated using a gelatin-gum arabic coacervate system. The microencapsulated product offers better controlled release for this drug when compared to standard table and powder forms.

Capsules↗
PubMed1994

Desensitizing effect of a potassium chloride dentifrice.

Sensodyne F is a potassium chloride (KCl) and sodium monofluorphosphate (MFP) containing dentifrice currently marketed in the United Kingdom and Germany was compared to a KCl only dentifrice and to a placebo dentifrice for effectiveness in alleviating dentin hypersensitivity. This 3-cell, randomized, double-blind, parallel clinical study utilized 62 subjects for an 8-week duration of product use. The degree of hypersensitivity of the affected teeth was assessed by tactile stimulation, cold air stimulation and overall subjective patient response. The results from these three methods of assessment indicated that a KCl containing dentifrice either alone or in combination with sodium MFP were significantly more effective than the placebo dentifrice in reducing dentin hypersensitivity. The therapeutic response to the KCl dentifrices as measured by air sensitivity and tactile sensitivity was statistically significant when compared to the placebo dentifrice within 4 weeks of use. Significant improvement was seen for all parameters at the conclusion of the 8-week clinical study period. Plaque reduction was significantly reduced at 8 weeks. The results indicate that KCl is an efficacious molecule in reducing dentin hypersensitivity when used either alone or in combination with sodium MFP as measured by improved overall patient comfort.

Adult↗
PubMed2004

[Effect of monocalcium phosphate and potassium chloride on nitrogen leaching in paddy soil].

In this article, influence of monocalcium phosphate and potassium chloride application on nitrogen leaching in paddy soil of Taihu region was studied by soil column leaching. The results showed that nitrate nitrogen was the main component of nitrogen leaching without urea application which accounts for 93.39 percent of total nitrogen leaching (including urea, ammonium, and nitrate nitrogen). Amounts of urea, ammonium, and nitrate nitrogen in leachates increased significantly after urea application which account for 3.95, 15.25, and 80.80 percent of total nitrogen leaching respectively and for 0.26, 0.80, and 2.54 percent of applied nitrogen respectively. Amounts of urea, ammonium, and nitrate nitrogen in leachates were enhanced prominently by monocalcium phosphate or potassium chloride which are 4.54, 24.11, 71.34, and 3.45, 24.53, 72.02 percent of total nitrogen leaching respectively, and which are 0.39, 1.86, 3.34, and 0.32, 2.12, 4.06 percent of applied nitrogen separately. There is interactive influence on nitrogen leaching after application of monocalcium phosphate and potassium chloride together, and amounts of urea, ammonium, and nitrate nitrogen were 4.10, 27.35, and 68.55 percent of total nitrogen leaching, and 0.42, 2.60, and 4.26 percent of total applied nitrogen respectively. The leaching order of different form nitrogen followed as urea N > ammonium N > nitrate N, and leaching amounts of different form nitrogen followed as urea N < ammonium N < nitrate N.

Ammonia↗
PubMed1985

Phentolamine and rat aortic smooth muscle responsiveness to potassium chloride, isoproterenol and norepinephrine.

Rat aortic smooth muscle responsiveness to potassium chloride and isoproterenol in the presence of the alpha-adrenergic blocker phentolamine was investigated. A A significant decrease in the response of the vascular smooth muscle of aorta to low concentrations of potassium chloride (KCl; 8-12 mM) in the presence of phentolamine was observed. However, no effect of phentolamine was seen at KCl concentrations greater than 16 mM. Isoproterenol-induced relaxation was significantly increased in aortic smooth muscle incubated with phentolamine. Phentolamine also attenuated the contraction induced by high concentrations of isoproterenol. No long-lasting effect of the alpha-adrenergic blocker was apparent since the response to norepinephrine was not altered following a 1-hour washout of phentolamine after the isoproterenol dose-response curve. The results of this study suggest that: (i) phentolamine has no long-lasting effects on rat aortic smooth muscle; (ii) since the rat thoracic aorta has a sparse adrenergic innervation, the decrease in responsiveness to KCl in the presence of phentolamine is most likely due to a nonspecific effect on the vascular smooth muscle as opposed to blocking the effects of norepinephrine released from adrenergic nerve terminals, and (iii) the increased relaxation response to isoproterenol may be due to a blockade of the alpha-receptors activated by isoproterenol.

Animals↗
PubMed1981

Potassium recycling in the renal medulla: effects of acute potassium chloride administration to rats fed a potassium-free diet.

According to the hypothesis of potassium recycling in the renal medulla, a portion of potassium in fluid in the medullary collecting duct is reabsorbed, trapped in the medullary interstitium by countercurrent exchange, and secreted in either the pars recta or descending limb of the juxtamedullary nephron. To examine the effects of an acute change in potassium balance on recycling, we performed a micropuncture study on the exposed papilla of 8 chloride. A second group of 6 rats was studied under identical conditions and infused with potassium chloride and amiloride. In the first group, the fraction of filtered potassium remaining at the end of the juxtamedullary descending limb increased with time to values over 100% concomitantly with the rise in urinary excretion of potassium. A strong association was found between those two variables (P less than 0.025). In the second group, in which the increase in urinary fractional excretion of potassium was prevented by amiloride, the rise in fractional of filtered potassium remaining at the end of the juxtamedullary nephron was abolished. These findings are interpreted as providing further support for the hypothesis of medullary recycling of potassium.

Amiloride↗
PubMed1992

[Comparison of two commercial potassium chloride tablets for slow-release in an in vitro dissolution test].

Two commercial slow-release potassium chloride tablets, Slow-K and Addi-K have the characteristics of slow-release in the different dissolution conditions. The two tablets had similar dissolution profiles in simulated intestinal fluid (pH 6.8), simulated gastric fluid (pH 1.2) and water; which indicates that, the dissolution rates of the two commercial potassium chloride tablets are independent of the pH values of the dissolution medium. The release patterns of potassium chloride fitted the First order model and Higuchi matrix model. These were distinguished by differential rate treatment, which showed that the release followed the First order pattern. It was found that the dissolution rate of Addi-K were more rapid than Slow-K in different dissolution conditions.

Delayed-Action Preparations↗
PubMed1988

An isotonic potassium chloride liquid junction minimises the effects of ionic strength, protein and haematocrit on ionised calcium measurement.

When the reference electrode liquid junction of a Nova 2 analyser was changed to isotonic potassium chloride, increasing the ionic strength of aqueous solutions containing a constant total calcium concentration had a negligible effect on measured ionised calcium. In contrast, measurements using hypertonic potassium chloride, hypertonic sodium formate and isotonic sodium chloride liquid junctions showed significant sample ionic strength effects. Interferences by sample protein concentration and haematocrit were marked with hypertonic, but negligible with isotonic junctions. Ionised calcium values in samples containing 25 mmol/L acetate, bicarbonate, beta-hydroxybutyrate, lactate or pyruvate were all lower by 6-7% with an isotonic than a hypertonic potassium chloride junction. Thus, anions that replace bicarbonate during metabolic acidosis have a similar effect on residual liquid junction potential. The clinical usefulness of an isotonic potassium chloride liquid junction needs to be evaluated.

Calcium↗
PubMed1989

Effect of dietary potassium chloride on feeder pig performance, market shrink, carcass traits and selected blood parameters.

A total of 288 commingled crossbred feeder pigs were purchased and transported 1,050 km in two trials to investigate the effect of added dietary potassium chloride in receiving and finishing diets on feeder pig shrink recovery, performance and pre-slaughter shrink. Diets containing 0, .48%, .96% or 1.44% added potassium chloride were fed for 2 wk post-arrival and again from 12 wk post- arrival until slaughter. There was no effect (P greater than .1) on gain (22.9 kg pay weight) or feed conversion or on plasma or red blood cell potassium for the 2-wk post-arrival period due to the inclusion of potassium chloride in the 2-wk receiving diet. Also, there was no effect (P greater than .1) of potassium chloride in diets from 12 wk post-arrival until slaughter on gain, feed conversion, market shrink, carcass dressing percentage and plasma or red blood cell potassium concentration at slaughter. These results suggest that corn-soybean meal-based diets contain sufficient potassium for pigs following a period of stress associated with marketing and transport.

Animal Feed↗
PubMed2006

Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension : a multicentre, randomised, open study.

BACKGROUND: The efficacy and safety of therapy with low-dose bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride was compared with that of enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension. STUDY DESIGN: This was a multicentre study in general practice with patients randomised in a double-blind fashion and on open-label treatment. After a washout phase that lasted 4-6 weeks, 312 patients with a diastolic blood pressure of between 100 and 115 mm Hg were randomised in a double-blind fashion to treatment with either bendroflumethiazide 1.25 mg/day and potassium chloride (n = 117), bendroflumethiazide 2.5 mg/day and potassium chloride (n = 60), amlodipine 5 mg/day (n = 61) or enalapril 10 mg/day (n = 60), all given once daily (numbers in parentheses indicate the intention-to-treat population, with a total of 298 patients). The primary efficacy parameter was the reduction in diastolic blood pressure. Effects on systolic blood pressure, heart rate, biochemical variables, adverse events and quality of life were studied as secondary efficacy parameters. RESULTS: All treatments reduced diastolic blood pressure significantly; reductions were as follows: 6.8 mm Hg with bendroflumethiazide 1.25 mg/day, 9.1 mm Hg with bendroflumethiazide 2.5 mg/day, 10.8 mm Hg with amlodipine 5 mg/day and 6.8 mm Hg with enalapril 10 mg/day. The reduction in diastolic blood pressure on amlodipine was significantly greater than on bendroflumethiazide 1.25 mg/day and enalapril 10 mg/day (p = 0.013). The percentage of patients achieving a diastolic blood pressure of < 95 mm Hg was 34% (SD 4.4) with bendroflumethiazide 1.25 mg/day, 48% (SD 6.5) with bendroflumethiazide 2.5 mg/day (p = 0.075 vs bendroflumethiazide 1.25 mg/day), 57% (SD 6.3) with amlodipine 5 mg/day (p = 0.004 vs bendroflumethiazide 1.25 mg/day) and 41% (SD 6.4) with enalapril 10 mg/day (p = 0.41 vs bendroflumethiazide 1.25 mg/day) [mean reductions]. The effect on systolic blood pressure was similar with all treatments. No clinically significant changes occurred in heart rate, serum potassium, blood glucose, serum urate or serum cholesterol levels. The incidences of adverse events were similar in the low-dose bendroflumethiazide groups, with significantly higher incidences in the enalapril and amlodipine groups. Quality of life was similar in the different treatment groups, but the study had limited power to detect any difference in this parameter. CONCLUSION: The present study has confirmed, in a general practice population, that low-dose bendroflumethiazide (bendroflumethiazide 1.25-2.5 mg/day) in combination with potassium chloride is a well tolerated and efficacious first-line treatment for patients with mild to moderate essential hypertension.

Adult↗